{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:56:25Z","timestamp":1791341785786,"version":"4.3.1"},"reference-count":108,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.eururo.2013.06.003","type":"journal-article","created":{"date-parts":[[2013,6,12]],"date-time":"2013-06-12T14:30:21Z","timestamp":1371047421000},"page":"639-653","source":"Crossref","is-referenced-by-count":1012,"title":["EAU Guidelines on Non\u2013Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013"],"prefix":"10.1016","volume":"64","author":[{"given":"Marko","family":"Babjuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Zigeuner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas W.G.","family":"van Rhijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Comp\u00e9rat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Sylvester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eero","family":"Kaasinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"B\u00f6hle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Palou Redorta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2013.06.003_bib0005","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0302-2838(01)00026-4","article-title":"Guidelines on bladder cancer","volume":"24","author":"Oosterlinck","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0010","unstructured":"Oxford Centre for Evidence-based Medicine levels of evidence (May 2001). Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawes since November 1998. Accessed May 2013."},{"key":"10.1016\/j.eururo.2013.06.003_bib0015","unstructured":"Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Globocan 2008: Cancer incidence and mortality worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer; 2010."},{"key":"10.1016\/j.eururo.2013.06.003_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eururo.2011.03.047","article-title":"Trends in mortality from urologic cancers in Europe, 1970\u20132008","volume":"60","author":"Bosetti","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1464-410X.2007.07239.x","article-title":"Declining mortality from bladder cancer in Europe","volume":"101","author":"Ferlay","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.06.003_bib0030","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0035","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2011.1142","article-title":"Association between smoking and risk of bladder cancer among men and women","volume":"306","author":"Freedman","year":"2011","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1016\/j.eururo.2013.06.003_bib0040","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1038\/bjc.2012.112","article-title":"Occupational cancer burden in Great Britain","volume":"107","author":"Rushton","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2013.06.003_bib0045","unstructured":"Sobin LH, Gospodariwicz M, Wittekind C, editors. TNM classification of malignant tumors. UICC International Union Against Cancer, ed. 7. Hoboken, NJ, USA: Wiley-Blackwell; 2009. p. 262\u20135."},{"key":"10.1016\/j.eururo.2013.06.003_bib0050","series-title":"WHO classification of tumours of the urinary system and male genital organs","article-title":"Tumours of the urinary system: non-invasive urothelial neoplasias","author":"Sauter","year":"2004"},{"key":"10.1016\/j.eururo.2013.06.003_bib0055","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.eururo.2009.03.052","article-title":"Prognostic accuracy of individual uropathologists in non-invasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation Classifications","volume":"57","author":"May","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0060","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.eururo.2009.09.022","article-title":"The pathologist's mean grade is constant and individualizes the prognostic value of bladder cancer grading","volume":"57","author":"van Rhijn","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0065","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1309\/AJCP12MRVVHTCKEJ","article-title":"Prognostic significance of the 2004 WHO\/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1,515 cases","volume":"133","author":"Pan","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0070","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1464-410X.2010.09515.x","article-title":"The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer","volume":"107","author":"Otto","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.06.003_bib0075","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1016\/j.juro.2011.07.070","article-title":"Clinical reliability of the 2004 WHO histological classification system compared with the 1973 WHO system for Ta primary bladder tumors","volume":"186","author":"Pellucchi","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0080","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.urology.2005.10.028","article-title":"Review pathology in a diagnostic bladder cancer trial","volume":"67","author":"Witjes","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2013.06.003_bib0085","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/S0022-5347(05)67022-X","article-title":"The role and impact of pathology review on stage and grade assessment on stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer trials","volume":"164","author":"Van der Meijden","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0090","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1464-410X.2009.09100.x","article-title":"Pathological stage review is indicated in primary pT1 bladder cancer","volume":"106","author":"Van Rhijn","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.06.003_bib0095","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S1078-1439(99)00020-4","article-title":"Updated concepts and treatment of carcinoma in situ","volume":"4","author":"Lamm","year":"1998","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0100","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0022-5347(01)65180-2","article-title":"Is routine excretory urography necessary at first diagnosis of bladder cancer?","volume":"157","author":"Goessl","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0105","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.ju.0000169424.79702.6d","article-title":"Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumours","volume":"174","author":"Palou","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0110","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0022-5347(05)67137-6","article-title":"Upper urinary tract tumours after primary superficial bladder tumours: prognostic factors and risk groups","volume":"164","author":"Mill\u00e1n-Rodr\u00edguez","year":"2000","journal-title":"J Urol"},{"issue":"Suppl 2","key":"10.1016\/j.eururo.2013.06.003_bib0115","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1038\/modpathol.2008.193","article-title":"Diagnosis of urothelial carcinoma from urine","volume":"22","author":"T\u00eatu","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0120","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0302-2838(02)00006-4","article-title":"Differences between local and review urinary cytology and diagnosis of bladder cancer. An interobserver multicenter analysis","volume":"41","author":"Raitanen","year":"2002","journal-title":"Eur Urol"},{"issue":"Suppl 1","key":"10.1016\/j.eururo.2013.06.003_bib0125","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.urology.2005.08.064","article-title":"Bladder tumour markers beyond cytology: international consensus panel on bladder tumour markers","volume":"66","author":"Lokeshwar","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2013.06.003_bib0130","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.eururo.2007.12.006","article-title":"Urinary markers in bladder cancer","volume":"53","author":"Vrooman","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0135","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.eursup.2009.06.008","article-title":"Cytology and urinary markers for the diagnosis of bladder cancer","volume":"8","author":"Van Rhijn","year":"2009","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2013.06.003_bib0140","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1001\/jama.293.7.810","article-title":"Detection of bladder cancer using a point-of-care proteomic assay","volume":"293","author":"Grossman","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2013.06.003_bib0145","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00345-007-0223-2","article-title":"Screening for bladder cancer: a perspective","volume":"26","author":"Lotan","year":"2008","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0150","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.eururo.2005.03.014","article-title":"Urine markers for bladder cancer surveillance: a systematic review","volume":"47","author":"Van Rhijn","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0155","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.295.3.299","article-title":"Surveillance for recurrent bladder cancer using a point-of-care proreomic assay","volume":"295","author":"Grossman","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2013.06.003_bib0160","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.urology.2007.12.021","article-title":"Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma","volume":"71","author":"Babjuk","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2013.06.003_bib0165","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.juro.2009.08.150","article-title":"Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial","volume":"183","author":"van der Aa","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0170","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1464-410X.2009.08417.x","article-title":"Meta-analysis: does lidocaine gel before flexible cystoscopy provide pain relief?","volume":"104","author":"Aaronson","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.06.003_bib0175","doi-asserted-by":"crossref","first-page":"E76","DOI":"10.1111\/j.1464-410X.2011.10904.x","article-title":"The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer","volume":"110","author":"Richterstetter","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.06.003_bib0180","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0302-2838(02)00068-4","article-title":"Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies","volume":"41","author":"Brausi","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0185","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.eururo.2009.05.047","article-title":"Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience","volume":"57","author":"Mariappan","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0190","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/j.1464-410X.2011.10571.x","volume":"109","author":"Mariappan","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.06.003_bib0195","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.juro.2007.05.148","article-title":"Management of low grade papillary bladder tumors","volume":"178","author":"Herr","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0200","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000019859","article-title":"Significance of bladder biopsies in Ta, T1 bladder tumours: a report of the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee","volume":"35","author":"Van der Meijden","year":"1999","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0205","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2011.10.029","article-title":"Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Gu\u00e9rin","volume":"62","author":"Palou","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0210","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.eururo.2005.05.021","article-title":"Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder","volume":"48","author":"Mungan","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0215","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.eururo.2005.03.021","article-title":"Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor","volume":"48","author":"Huguet","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0220","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.eururo.2009.11.041","article-title":"Photodynamic diagnosis in non\u2013muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies","volume":"57","author":"Kausch","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0225","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1017\/S0266462310001364","article-title":"Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: systematic review and meta-analysis","volume":"27","author":"Mowatt","year":"2011","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.eururo.2013.06.003_bib0230","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.eururo.2009.09.037","article-title":"Photodynamic diagnosis (5 aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Gu\u00e9rin immunotherapy and mitomycin C intravesical therapy","volume":"57","author":"Draga","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0235","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1464-410X.2009.08839.x","article-title":"Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Gu\u00e9rin","volume":"105","author":"Ray","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.06.003_bib0240","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.eururo.2009.10.030","article-title":"Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic acid under visible and fluorescent light: results of a prospective, randomised, multicentre study","volume":"57","author":"Schumacher","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0245","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/cncr.25523","article-title":"Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy: a multicenter randomized, double-blind, placebo-controlled trial","volume":"117","author":"Stenzl","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2013.06.003_bib0250","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.juro.2012.03.007","article-title":"Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy","volume":"188","author":"Grossman","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0255","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0302-2838(03)00040-X","article-title":"The value of a second transurethral resection in evaluating patients with bladder tumours","volume":"43","author":"Miladi","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0260","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0022-5347(05)01002-5","article-title":"The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumours of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial","volume":"175","author":"Divrik","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0265","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.eururo.2003.09.018","article-title":"Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis","volume":"45","author":"Lopez-Beltran","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0270","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0275","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0280","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.urology.2008.12.047","article-title":"Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors","volume":"73","author":"Palou","year":"2009","journal-title":"Urology"},{"issue":"Suppl 1","key":"10.1016\/j.eururo.2013.06.003_bib0285","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.urology.2005.06.135","article-title":"High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder","volume":"66","author":"Sylvester","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2013.06.003_bib0290","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.juro.2010.03.032","article-title":"Clinical outcomes of primary bladder carcinoma in situ in a contemporary series","volume":"184","author":"Chade","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0295","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.juro.2011.07.076","article-title":"A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group","volume":"186","author":"Brausi","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0300","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1097\/01.ju.0000168657.51551.49","article-title":"Inhibition of tumor implantation by intravesical gemcitabine in a murine model of superficial bladder cancer","volume":"174","author":"Brocks","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0305","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0022-5347(17)36198-0","volume":"149","author":"Oosterlinck","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0310","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1097\/01.ju.0000125486.92260.b2","article-title":"A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a metaanalysis of published results of randomized clinical trials","volume":"171","author":"Sylvester","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0315","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.juro.2007.08.166","article-title":"A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences","volume":"179","author":"Berrum-Svennung","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0320","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.eururo.2009.01.006","article-title":"Should all patients with non\u2013muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study","volume":"55","author":"Gudjonsson","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0325","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S0022-5347(01)67608-0","volume":"153","author":"Bouffioux","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0330","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0302-2838(02)00260-9","article-title":"Factors explaining recurrence in patients undergoing chemo-immunotherapy regimens for frequently recurring superficial bladder carcinoma","volume":"42","author":"Kaasinen","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0335","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0022-5347(01)66226-8","article-title":"The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up","volume":"155","author":"Tolley","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0340","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S0022-5347(17)44926-3","article-title":"The mechanism of human bladder tumor implantation in an in vitro model","volume":"136","author":"Pode","year":"1986","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0345","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.eururo.2004.05.003","article-title":"One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe?","volume":"46","author":"Oddens","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0350","first-page":"765","article-title":"Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis","volume":"21","author":"Huncharek","year":"2001","journal-title":"Anticancer Res"},{"key":"10.1016\/j.eururo.2013.06.003_bib0355","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.eururo.2008.01.015","article-title":"The schedule and duration of intravesical chemotherapy in patients with non\u2013muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials","volume":"53","author":"Sylvester","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0360","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eururo.2011.04.023","article-title":"The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non\u2013muscle-invasive bladder cancer: a systematic review","volume":"60","author":"Lammers","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0365","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","article-title":"Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial","volume":"7","author":"Di Stasi","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0370","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/jnci\/93.8.597","article-title":"Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial","volume":"93","author":"Au","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2013.06.003_bib0375","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.eururo.2003.12.010","volume":"45","author":"Kuroda","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0380","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the longterm outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non\u2013muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0385","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1464-410x.2001.02306.x","article-title":"A systematic review of intravesical bacillus Calmette-Gu\u00e9rin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer","volume":"88","author":"Shelley","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.06.003_bib0390","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","article-title":"Can intravesical bacillus Calmette-Gu\u00e9rin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials","volume":"67","author":"Han","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2013.06.003_bib0395","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1464-410X.2003.04655.x","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a metaanalysis of randomized trials","volume":"93","author":"Shelley","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.06.003_bib0400","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"B\u00f6hle","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0405","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.eururo.2009.09.038","article-title":"Bacillus Calmette-Gu\u00e9rin is superior to a combination of epirubicin and interferon-a2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study","volume":"57","author":"Duchek","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0410","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eururo.2009.04.009","volume":"56","author":"J\u00e4rvinen","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0415","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0420","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumour progression","volume":"63","author":"B\u00f6hle","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2013.06.003_bib0425","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0430","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0435","first-page":"CD006885","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin versus epirubicin for Ta and T1 bladder cancer","author":"Shang","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2013.06.003_bib0440","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","article-title":"Maintenance bacillus Calmette-Guerin for Ta, T1 bladder tumours is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial","volume":"44","author":"Van der Meijden","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0445","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.juro.2011.10.032","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin outcomes in patients with bladder cancer and asymptomatic bacteriuria","volume":"187","author":"Herr","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0540","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.juro.2006.03.066","article-title":"Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients","volume":"176","author":"Yossepowitch","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0450","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.eursup.2008.08.001","article-title":"Clinical practice recommendations for the prevention and management of intravesical therapy-associated adverse events","volume":"7","author":"Witjes","year":"2008","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2013.06.003_bib0455","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","article-title":"Long-term follow-up of a randomized prospective trial comparing a standard 81mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27mg in superficial bladder cancer","volume":"89","author":"Mart\u00ednez-Pi\u00f1eiro","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.06.003_bib0460","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/01.ju.0000173919.28835.aa","article-title":"Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial","volume":"174","author":"Mart\u00ednez-Pi\u00f1eiro","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0465","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","article-title":"A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27mg) versus very low-dose bacillus Calmette-Guerin (13.5mg) versus mitomycin C","volume":"52","author":"Ojea","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0470","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette-Guerin versus chemotherapy in the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0475","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0022-5347(01)66338-9","article-title":"Extravesical involvement in patients with bladder carcinoma in situ: biological and therapy implications","volume":"155","author":"Solsona","year":"1996","journal-title":"J Urol"},{"issue":"Suppl","key":"10.1016\/j.eururo.2013.06.003_bib0480","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.urology.2006.05.059","article-title":"Urothelial carcinoma of the prostate","volume":"69","author":"Palou","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2013.06.003_bib0490","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.eururo.2012.08.055","article-title":"Treatment options available for bacillus Calmette-Gu\u00e9rin failure in non-muscle-invasive bladder cancer","volume":"62","author":"Yates","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0495","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.juro.2009.06.017","article-title":"Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin","volume":"182","author":"Nativ","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0500","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0505","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/cncr.24914","article-title":"Gemcitabine versus bacille Calmette-Gu\u00e9rin after initial bacille Calmette-Gu\u00e9rin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial","volume":"116","author":"Di Lorenzo","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2013.06.003_bib0510","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.urolonc.2007.11.033","article-title":"Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non muscle invasive bladder cancer","volume":"27","author":"Lerner","year":"2009","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0485","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.urology.2007.09.050","article-title":"Impact of previous bacille Calmette-Gu\u00e9rin failure pattern on subsequent response to bacille Calmette-Gu\u00e9rin plus interferon intravesical therapy","volume":"71","author":"Gallagher","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2013.06.003_bib0515","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.juro.2006.11.090","article-title":"Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer","volume":"177","author":"Raj","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0520","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.eururo.2005.12.029","article-title":"Watchful waiting policy in recurrent Ta G1 bladder tumors","volume":"49","author":"Gofrit","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0525","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1097\/01.ju.0000149163.08521.69","article-title":"A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database","volume":"173","author":"Mariappan","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0530","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.eururo.2012.05.008","article-title":"Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature","volume":"62","author":"Soukup","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.003_bib0535","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.eururo.2011.11.011","article-title":"Should follow-up cystoscopy in bacillus Calmette-Gu\u00e9rin-treated patients continue after five tumour-free years?","volume":"61","author":"Holm\u00e4ng","year":"2012","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283813006015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283813006015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T08:53:47Z","timestamp":1715504027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283813006015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":108,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0302283813006015"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2013.06.003","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}